{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:16:34Z","timestamp":1792516594872,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007342","name":"Hamdard National Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.xphs.2018.07.021","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T12:22:08Z","timestamp":1533126128000},"page":"2914-2926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Adaptation of Quality by Design-Based Development of Isradipine Nanostructured\u2013Lipid Carrier and Its Evaluation for In\u00a0Vitro Gut Permeation and In\u00a0Vivo Solubilization Fate"],"prefix":"10.1016","volume":"107","author":[{"given":"Tausif","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Faheem","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjula","family":"Baboota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2018.07.021_bib1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jfoodeng.2005.11.024","article-title":"Modeling and optimization I: usability of response surface methodology","volume":"78","author":"Bas","year":"2007","journal-title":"J\u00a0Food Eng"},{"key":"10.1016\/j.xphs.2018.07.021_bib2","unstructured":"Zhen HE, Xu-tao Z and Gui-qing X. Product quality improvement through response surface methodology: a case study. Presented during the Proceedings of 2013 International Conference on Technology Innovation and Industrial Management: Phuket, Thailand; May 2013:S4-120-130."},{"issue":"4","key":"10.1016\/j.xphs.2018.07.021_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/10837450.2013.795169","article-title":"Preparation, in\u00a0vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration","volume":"19","author":"Shah","year":"2014","journal-title":"Pharm Dev Technol"},{"issue":"3","key":"10.1016\/j.xphs.2018.07.021_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1208\/s12249-018-0951-1","article-title":"Risk assessment integrated QbD approach for development of optimized bicontinuous mucoadhesive limicubes for oral delivery of rosuvastatin","volume":"19","author":"Javed","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2018.07.021_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.foodchem.2015.12.061","article-title":"Preservation of anthocyanins in solid lipid nanoparticles: optimization of a microemulsion dilution method using the Placket\u2013Burman and Box\u2013Behnken designs","volume":"199","author":"Ravanfar","year":"2016","journal-title":"Food Chem"},{"key":"10.1016\/j.xphs.2018.07.021_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cej.2011.02.061","article-title":"Using the Box\u2013Benkhen design (BBD) to minimize the diameter of electrospun titanium dioxide nanofibers","volume":"169","author":"Ray","year":"2011","journal-title":"Chem Eng J"},{"key":"10.1016\/j.xphs.2018.07.021_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijpharm.2009.12.040","article-title":"Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett\u2013Burman design","volume":"389","author":"Rahman","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpb.2016.10.011","article-title":"Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in\u00a0vivo bioavailability enhancement","volume":"109","author":"Khan","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib9","doi-asserted-by":"crossref","first-page":"96S","DOI":"10.1093\/ajh\/4.2.96S","article-title":"The place of isradipine in the treatment of hypertension","volume":"4","author":"Veld","year":"1991","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.xphs.2018.07.021_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchromb.2008.11.021","article-title":"Quantification of isradipine in human plasma using LC\u2013MS\/MS for pharmacokinetic and bioequivalence study","volume":"877","author":"Park","year":"2009","journal-title":"J\u00a0Chromatogr B"},{"issue":"5","key":"10.1016\/j.xphs.2018.07.021_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/03639045.2014.900081","article-title":"Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in\u00a0vitro and in\u00a0vivo evaluation","volume":"41","author":"Ramasahayam","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.onano.2016.03.002","article-title":"Optimization and in-vivo evaluation of isradipine nanoparticles using Box-Behnken design surface response methodology","volume":"1","author":"Venugopal","year":"2016","journal-title":"OpenNano"},{"key":"10.1016\/j.xphs.2018.07.021_bib13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijbiomac.2016.07.020","article-title":"Optimization & design of isradipine loaded solid lipidnanobioparticles using rutin by Taguchi methodology","volume":"92","author":"Kumar","year":"2016","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.xphs.2018.07.021_bib14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/17425247.2015.1005072","article-title":"Immunosuppressive drug therapy-biopharmaceutical challenges and remedies","volume":"12","author":"Khan","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2018.07.021_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2010.10.017","article-title":"Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in\u00a0vitro by everted gut sac and in situ by improved intestinal perfusion","volume":"403","author":"Li","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2003","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.xphs.2018.07.021_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0731-7085(99)00173-9","article-title":"Photodegradation of inclusion complexes of isradipine with methyl-b-cyclodextrin","volume":"21","author":"Mielcarek","year":"1999","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2018.07.021_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejpb.2016.07.017","article-title":"Tacrolimus-loaded nanostructured lipid carriers for oral delivery -optimization of production & characterization","volume":"108","author":"Khan","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.colsurfb.2013.12.012","article-title":"Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride","volume":"116","author":"Ranpise","year":"2014","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.xphs.2018.07.021_bib20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.molliq.2018.01.141","article-title":"Silymarin loaded nanostructured lipid carrier: from design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement","volume":"255","author":"Iqbal","year":"2018","journal-title":"J\u00a0Mol Liq"},{"key":"10.1016\/j.xphs.2018.07.021_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijpharm.2013.03.034","article-title":"Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization","volume":"454","author":"Shete","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/17425247.2014.945416","article-title":"Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in\u00a0vitro characterization and in\u00a0vivo efficacy in epilepsy","volume":"12","author":"Alam","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2018.07.021_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ultsonch.2017.09.042","article-title":"Ultrasonically tailored, chemically engineered and \u201cQbD\u201d enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study","volume":"41","author":"Ahmed","year":"2018","journal-title":"Ultrason Sonochem"},{"key":"10.1016\/j.xphs.2018.07.021_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpharm.2010.12.036","article-title":"Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure","volume":"406","author":"Kovacevic","year":"2011","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2018.07.021_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1039\/C7NR07736J","article-title":"Stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers","volume":"10","author":"Shrestha","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.xphs.2018.07.021_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsps.2015.03.008","article-title":"Enhanced ex\u00a0vivo intestinal absorption of olmesartan medoxomil nanosuspension: preparation by combinative technology","volume":"24","author":"Attari","year":"2016","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.xphs.2018.07.021_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsps.2010.02.005","article-title":"Influence of intestinal efflux pumps on the absorption and transport of furosemide","volume":"18","author":"Abdullah","year":"2010","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.xphs.2018.07.021_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2014.09.052","article-title":"Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin","volume":"476","author":"Liu","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2011.05.044","article-title":"Nanostructured lipid Carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake","volume":"415","author":"Tiwari","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2018.07.021_bib30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejps.2009.04.008","article-title":"Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin","volume":"37","author":"Subedi","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2018.07.021_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jfoodeng.2018.03.006","article-title":"Development and characterization of solid lipid nanoparticles (SLNs) made of cocoa butter: a factorial design study","volume":"231","author":"Shtay","year":"2018","journal-title":"J\u00a0Food Eng"},{"key":"10.1016\/j.xphs.2018.07.021_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2011.06.004","article-title":"Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan","volume":"8","author":"Ahad","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.xphs.2018.07.021_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-0773.2000.860405.x","article-title":"Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?","volume":"86","author":"Christensen","year":"2000","journal-title":"Pharmacol Toxicol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918304568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918304568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:24:23Z","timestamp":1758360263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918304568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0022354918304568"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.07.021","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptation of Quality by Design-Based Development of Isradipine Nanostructured\u2013Lipid Carrier and Its Evaluation for In\u00a0Vitro Gut Permeation and In\u00a0Vivo Solubilization Fate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}